A deal between Medivation and BioMarin for cancer asset talazoparib exemplifies the sort of deals the industry saw from big pharma last year as BioMarin tries to focus on its area of strength – rare disease drugs.
The two biotechs announced Aug. 24 that BioMarin will divest its late-stage orally-available poly ADP ribose polymerase (PARP) inhibitor to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?